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Methods
Results
Conclusions
We report on the performance of a novel prothrombin time
reagent (NewPT) which utilises human recombinant tissue factor
produced by silkworm technology and synthetic phospholipids.
Insect systems are widely used to produce proteins from higher
eukaryotes because they have a similar pattern of glycosylation,
phosphorylation, and protein processing.
The aim of this study was to compare the performance of NewPT
with two widely used PT reagents.
The performance of NewPT (Sysmex Corp. Japan) was
compared to that of two commercial PT reagents containing
either recombinant human tissue factor (A) or human placental
thromboplastin (B) on a fully automated coagulometer. Analyser
specific ISI values were determined using Technoclone AK-
Calibrant as per SSC guidelines were used. On-board stability
and imprecision were assessed using commercial QC
preparations. Comparability testing was performed on over 300
normal and abnormal plasma samples.
Normal reference ranges were established in 100 normal healthy 
donors (Table 1). Excellent between-day imprecision was 
obtained for all 3 reagents and acceptable on-board stability was 
observed. 
Table 1.
Fig. 1.  INR values for normal controls (n = 100)  and patients 
receiving warfarin (n = 130). PTA vs NewPT
Fig. 2.  INR values for normal controls (n = 100)  and patients 
receiving warfarin (n = 130). PTB vs NewPT
Good agreement was obtained between methods in 130
samples from patients receiving warfarin. The FII sensitivity of
NewPT was similar to reagents A and B but NewPT was more
sensitive to FV, FVII and FX. NewPT had similar sensitivity to
reagent B for coagulation defects in liver disease and improved
sensitivity compared to reagent A.
No heparin interference was observed in plasma spiked with up
to 1.5 IU/mL unfractionated heparin or low molecular weight
heparin in NewPT or reagent A both of which contain a heparin-
neutralising compound.
The lupus anticoagulant sensitivity of all three reagents was
similar. NewPT demonstrated dose responsiveness to
Dabigatran, Apixaban and Rivaroxaban with steeper response
curves than Reagent A or B.
In a wide range of plasma samples, sbPT
demonstrated comparable or improved performance
relative to two commercial PT reagents which are
suitable for the control of oral vitamin K antagonist
therapy and the detection of congenital or acquired
deficiency of FII, FV, FVII and FX.
NewPT PT reagent A PT reagent B
Normal range (s) n = 100 9.78-12.89 9.60 – 11.54 11.33 – 13.75
ISI 1 0.97 1.07
Between day imprecision % CV 
normal QC ; abnormal QC 0.81; 0.83 0.78; 1.55 1.30; 1.24
4 day on-board stability (% of day 
0) -2.1 to -0.8 -4.8 to -0.8 -3.9 to 0.7
Mean INR (Warfarin, n = 130) 3.06 3.02 3.09
Mean INR in warfarin LA plasmas 
(n = 53) 1.87 1.87 1.62
